| P2093 | author name string | Shawna Nesbitt | |
| | Addison A Taylor | |
| | Helmy Siragy | |
| P2860 | cites work | Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes | Q28188162 |
| | The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes | Q28188182 |
| | Role of angiotensin II in cardiovascular disease therapeutic implications of more than a century of research | Q28272171 |
| | Progressive effects of valsartan compared with amlodipine in prevention of diabetes according to categories of diabetogenic risk in hypertensive patients: the VALUE trial | Q28286410 |
| | Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy | Q29615215 |
| | Telmisartan, ramipril, or both in patients at high risk for vascular events | Q33156143 |
| | Platelet aggregability in patients with hypertension treated with angiotensin II type 1 receptor blockers | Q33276389 |
| | Antiplatelet effect of losartan and telmisartan in patients with ischemic stroke | Q33298463 |
| | Redox signaling, vascular function, and hypertension | Q33689229 |
| | Newly emerging pharmacologic differences in angiotensin II receptor blockers | Q33839710 |
| | Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity | Q33976477 |
| | Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (A | Q33989952 |
| | Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial | Q34327991 |
| | Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study | Q34494252 |
| | Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. | Q46426098 |
| | Effects of valsartan and perindopril combination therapy on left ventricular hypertrophy and aortic arterial stiffness in patients with essential hypertension | Q46511453 |
| | Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy | Q46581957 |
| | The relationship between the plasma concentration of irbesartan and the antihypertensive response is disclosed by an angiotensin II type 1 receptor polymorphism: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs. Aten | Q46606291 |
| | Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy | Q46616440 |
| | Inhibition of cardiovascular cell proliferation by angiotensin receptor blockers: are all molecules the same? | Q46656510 |
| | Comparative antihypertensive efficacy of angiotensin receptor blocker-based treatment in African-American and white patients | Q46755592 |
| | Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg | Q56419300 |
| | Feasibility of treating prehypertension with an angiotensin-receptor blocker | Q34502178 |
| | Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol | Q34522261 |
| | Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis | Q34604680 |
| | Current concepts of pharmacotherapy in hypertension: ACE inhibitor-related angioedema: can angiotensin-receptor blockers be safely used? | Q34943367 |
| | 24-Hour ambulatory blood pressure control with triple-therapy amlodipine, valsartan and hydrochlorothiazide in patients with moderate to severe hypertension | Q35219694 |
| | Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists: beyond the renin-angiotensin system | Q35991206 |
| | Possible pathophysiologic mechanisms supporting the superior stroke protection of angiotensin receptor blockers compared to angiotensin-converting enzyme inhibitors: clinical and experimental evidence | Q36210252 |
| | Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials | Q36247551 |
| | The pleiotropic effects of angiotensin receptor blockers | Q36440956 |
| | Vascular inflammation in hypertension and diabetes: molecular mechanisms and therapeutic interventions. | Q36745694 |
| | Vascular cognitive impairment: current concepts and clinical developments | Q37085101 |
| | Left ventricular hypertrophy and clinical outcomes in hypertensive patients | Q37147735 |
| | Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial | Q37197711 |
| | Risk of angioedema with angiotensin receptor blockers in patients with prior angioedema associated with angiotensin-converting enzyme inhibitors: a meta-analysis | Q37340888 |
| | Oxidative stress and hypertension | Q37475559 |
| | Has pharmacogenetics brought us closer to 'personalized medicine' for initial drug treatment of hypertension? | Q37513040 |
| | The current state of RAAS blockade in the treatment of hypertension and proteinuria | Q37623107 |
| | Differences in pharmacology and their translation into differences in clinical efficacy--a comparison of the renin angiotensin blocking agents irbesartan and losartan | Q37661553 |
| | Pleiotropic effects of inhibitors of the RAAS in the diabetic population: above and beyond blood pressure lowering | Q37738157 |
| | Pleiotropic effects of angiotensin receptor blockers: addressing comorbidities by optimizing hypertension therapy | Q37826797 |
| | Triple therapy with olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide in adult patients with hypertension: The TRINITY multicenter, randomized, double-blind, 12-week, parallel-group study | Q38371522 |
| | Long-term safety and efficacy of aliskiren and valsartan combination with or without the addition of HCT in patients with hypertension | Q38497893 |
| | C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women | Q40608305 |
| | Microalbuminuria predicts cardiovascular events and renal insufficiency in patients with essential hypertension | Q40842306 |
| | Valsartan improves arterial stiffness in type 2 diabetes independently of blood pressure lowering | Q42165612 |
| | Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial | Q42542786 |
| | Differential effects between a calcium channel blocker and a diuretic when used in combination with angiotensin II receptor blocker on central aortic pressure in hypertensive patients | Q42630158 |
| | Effect of ACE insertion/deletion and 12 other polymorphisms on clinical outcomes and response to treatment in the LIFE study | Q43197135 |
| | Inhibition of platelet activation in stroke-prone spontaneously hypertensive rats: comparison of losartan, candesartan, and valsartan. | Q43573754 |
| | Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension | Q43757678 |
| | A role for uric acid in the progression of renal disease | Q44223958 |
| | The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial | Q44417511 |
| | Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: The Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study | Q44529174 |
| | Efficacy of various antihypertensive agents as evaluated by indices of vascular stiffness in elderly hypertensive patients | Q44624009 |
| | Adherence to antihypertensive therapy with fixed-dose amlodipine besylate/benazepril HCl versus comparable component-based therapy | Q44701637 |
| | Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial | Q44979740 |
| | Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension study | Q45176683 |
| | Combination therapy with various combinations of aliskiren, valsartan, and hydrochlorothiazide in hypertensive patients not adequately responsive to hydrochlorothiazide alone. | Q45968750 |
| | Triple antihypertensive therapy with amlodipine, valsartan, and hydrochlorothiazide: a randomized clinical trial. | Q45995805 |
| | Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients | Q46217490 |
| P433 | issue | 9 | |
| P921 | main subject | pharmacology | Q128406 |
| P304 | page(s) | 677-686 | |
| P577 | publication date | 2011-07-27 | |
| P1433 | published in | Journal of Clinical Hypertension | Q15764150 |
| P1476 | title | Angiotensin receptor blockers: pharmacology, efficacy, and safety | |
| P478 | volume | 13 | |